These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 20538763)

  • 1. PIKing the right patient.
    Turke AB; Engelman JA
    Clin Cancer Res; 2010 Jul; 16(14):3523-5. PubMed ID: 20538763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
    O'Brien C; Wallin JJ; Sampath D; GuhaThakurta D; Savage H; Punnoose EA; Guan J; Berry L; Prior WW; Amler LC; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2010 Jul; 16(14):3670-83. PubMed ID: 20453058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
    Zheng J; Wang H; Yao J; Zou X
    Pharmazie; 2014 Jan; 69(1):38-42. PubMed ID: 24601221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
    Hoeflich KP; Merchant M; Orr C; Chan J; Den Otter D; Berry L; Kasman I; Koeppen H; Rice K; Yang NY; Engst S; Johnston S; Friedman LS; Belvin M
    Cancer Res; 2012 Jan; 72(1):210-9. PubMed ID: 22084396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
    Wallin JJ; Guan J; Prior WW; Edgar KA; Kassees R; Sampath D; Belvin M; Friedman LS
    Sci Transl Med; 2010 Sep; 2(48):48ra66. PubMed ID: 20826841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
    Salphati L; Wong H; Belvin M; Bradford D; Edgar KA; Prior WW; Sampath D; Wallin JJ
    Drug Metab Dispos; 2010 Sep; 38(9):1436-42. PubMed ID: 20538720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PI3K and MEK: it is all about combinations and biomarkers.
    Rexer BN; Ghosh R; Arteaga CL
    Clin Cancer Res; 2009 Jul; 15(14):4518-20. PubMed ID: 19584146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
    Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
    Kurokawa H; Lenferink AE; Simpson JF; Pisacane PI; Sliwkowski MX; Forbes JT; Arteaga CL
    Cancer Res; 2000 Oct; 60(20):5887-94. PubMed ID: 11059787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.
    Zheng L; Yang W; Zhang C; Ding WJ; Zhu H; Lin NM; Wu HH; He QJ; Yang B
    Cancer Lett; 2011 Oct; 309(1):27-36. PubMed ID: 21664043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 signatures in breast cancer: ready to go to print?
    Eichhorn PJ; Baselga J
    J Clin Oncol; 2010 Apr; 28(11):1809-10. PubMed ID: 20231675
    [No Abstract]   [Full Text] [Related]  

  • 14. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
    Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
    Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
    Niu G; Carter WB
    Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase.
    O'Hagan RC; Hassell JA
    Oncogene; 1998 Jan; 16(3):301-10. PubMed ID: 9467955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Chou B; Halladay JS; Olivero AG; Rudewicz PJ; Tian Q; Wong S; Zhang X
    Xenobiotica; 2011 Dec; 41(12):1088-99. PubMed ID: 21838594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.